Uncovering the Challenges in Treatment Pathways in AMD and DME

This activity is part 1 in a 3-part webinar curriculum.

Add-on activity

This activity includes a Powered by Patients™ interview.

Program Description

Age-related macular degeneration (AMD) and diabetic macular edema (DME) are 2 leading causes of vision loss and impose a significant burden on patients and the health care system. The overlapping pathophysiology of both conditions requires that pharmacists be able to distinguish between their clinical presentations, risk factors, and progression. This webinar will tackle current treatment challenges in AMD and DME, addressing the importance of screening, limitations in medication dosing and adherence, and burdens associated with injection frequency. Additionally, management of AMD and DME, including medications and injections, can be expensive. Patients experience the significant impact of visual function impairment in both social limitations as well as increased health care resource utilization. This webinar will provide specialty pharmacists with valuable insights to enhance their role within ophthalmology care in managing therapies for patients with AMD and DME to improve patient quality of life and reduce associated disease burden. A Powered by Patients™ interview will be included within the presentation, featuring the perspective of an individual living with AMD/DME and their experience in navigating treatment challenges with the help of a multidisciplinary team.

Target audience: Specialty pharmacists

Type of activity: Application
Release date: August 9, 2024
Expiration date: August 9, 2025

Time to complete activity: 1.0 hour

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply knowledge of the pathophysiology of age-related macular degeneration (AMD) and diabetic macular edema (DME) to differentiate between the clinical presentation and disease progression of each condition
• Analyze current treatment challenges associated with AMD, including the role of screening, the frequency of anti-vascular endothelial growth factor injections, and the limitations of therapies pertaining to dosing regimens and adherence
• Explain the significant quality of life burden for patients with DME, including risk factors, its impact on visual function, and health care resource utilization

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-237-H01-P. The activity is available for CE credit through August 9, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Sunir J. Garg, MD, FACS, FASRS, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: American Academy of Ophthalmology, Apellis, Boehringer Ingelheim, Genentech, NGM Biopharmaceuticals Inc, Regeneron, Kodiak Biosciences

Consultant: American Academy of Ophthalmology, Apellis, Bausch & Lomb, Boehringer Ingelheim, Merck Manual, Regeneron, Roche Genentech, West Pharmaceuticals

Other:

Lecture fees: Canadian Ophthalmological Society, Cole Eye Institute Retina Summit, Physicians' Education Resource, Retina Fellows Forum

Advisory Board: Coherus BioSciences

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms